Seeking Turnaround, Myrexis Taps Two New Execs
This article was originally published in The Pink Sheet Daily
Executive Summary
Rather than pursue a sale, Myrexis will obtain revenue-generating drugs that it feels are underperforming in other hands. Until it chooses an asset to acquire, it will operate as a virtual company.